These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16198984)

  • 1. Modulation of cytochrome P450 activity: implications for cancer therapy.
    Scripture CD; Sparreboom A; Figg WD
    Lancet Oncol; 2005 Oct; 6(10):780-9. PubMed ID: 16198984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
    Rochat B
    Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
    Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
    Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH
    Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
    Lee IS; Kim D
    Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multidrug-resistance by induction of inactivation for anti-cancer drugs].
    Ishii I; Kitada M
    Nihon Rinsho; 1997 May; 55(5):1044-9. PubMed ID: 9155150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
    Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
    Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
    Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
    Chang TK; Yu L; Maurel P; Waxman DJ
    Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L; Waxman DJ
    Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
    Jounaidi Y; Hecht JE; Waxman DJ
    Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
    Yu L; Waxman DJ
    Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.
    Monsarrat B; Royer I; Wright M; Cresteil T
    Bull Cancer; 1997 Feb; 84(2):125-33. PubMed ID: 9180834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
    Rochat B; Morsman JM; Murray GI; Figg WD; McLeod HL
    J Pharmacol Exp Ther; 2001 Feb; 296(2):537-41. PubMed ID: 11160641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.
    Ng SF; Waxman DJ
    Cancer Res; 1991 May; 51(9):2340-5. PubMed ID: 1707751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome p450 and chemical toxicology.
    Guengerich FP
    Chem Res Toxicol; 2008 Jan; 21(1):70-83. PubMed ID: 18052394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
    Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
    Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.